HCM
REGN icon

Harvey Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Harvey Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.71M Sell
9,976
-222
-2% -$170K 1.76% 14
2025
Q4 		$7.87M Sell
10,198
-1,204
-11% -$818K 1.68% 17
2025
Q3 		$6.41M Sell
11,402
-340
-3% -$192K 1.37% 16
2025
Q2 		$6.28M Sell
11,742
-1,350
-10% -$753K 1.47% 19
2025
Q1 		$8.3M Buy
13,092
+28
+0.2% +$19.3K 2.17% 13
2024
Q4 		$9.31M Buy
13,064
+242
+2% +$203K 2.19% 9
2024
Q3 		$13.5M Sell
12,822
-35
-0.3% -$39K 3.37% 7
2024
Q2 		$13.5M Sell
12,857
-70
-0.5% -$67.9K 3.55% 6
2024
Q1 		$12.4M Sell
12,927
-77
-0.6% -$73.2K 3.64% 6
2023
Q4 		$11.4M Sell
13,004
-127
-1% -$105K 3.79% 7
2023
Q3 		$10.8M Sell
13,131
-30
-0.2% -$23.6K 3.8% 7
2023
Q2 		$9.46M Buy
13,161
+581
+5% +$448K 3.48% 7
2023
Q1 		$10.3M Sell
12,580
-140
-1% -$106K 4.07% 7
2022
Q4 		$9.18M Sell
12,720
-10
-0.1% -$7.38K 3.84% 6
2022
Q3 		$8.77M Sell
12,730
-3,080
-19% -$1.94M 3.8% 6
2022
Q2 		$9.35M Sell
15,810
-1,083
-6% -$704K 3.64% 6
2022
Q1 		$11.8M Buy
16,893
+98
+0.6% +$62K 3.64% 7
2021
Q4 		$10.6M Buy
16,795
+1,033
+7% +$635K 3.29% 8
2021
Q3 		$9.54M Sell
15,762
-1,400
-8% -$869K 3.27% 8
2021
Q2 		$9.59M Buy
17,162
+6,105
+55% +$3.09M 3.16% 9
2021
Q1 		$5.23M Buy
+11,057
New +$5.38M 1.9% 19
2020
Q4 		– Sell
-400
Closed -$223K – 81
2020
Q3 		$223K Sell
400
-50
-11% -$30.3K 0.1% 70
2020
Q2 		$280K Buy
+450
New +$255K 0.14% 61

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Harvey Capital Management's REGN Position: Q1 2026 in Review

Harvey Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.2% in Q1 2026, selling an estimated $170K and leaving 9,976 shares worth $7.71M. The position accounts for 1.76% of the portfolio, ranked #14.

Harvey Capital Management first reported a position in REGN in Q2 2020 and has held it in 23 quarters since. The position peaked at $13.5M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Harvey Capital Management held 9,976 shares of Regeneron Pharmaceuticals worth $7.71M as of Q1 2026.
  • Harvey Capital Management sold 222 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $170K.
  • Regeneron Pharmaceuticals made up 1.76% of Harvey Capital Management's portfolio in Q1 2026, its #14 holding.
  • Harvey Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Harvey Capital Management's Regeneron Pharmaceuticals position peaked at $13.5M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Harvey Capital Management's 13F filing for Q1 2026, filed 11 May 2026.